Athena Athena

X
[{"orgOrder":0,"company":"Vensica Therapeutics","sponsor":"Merz Therapeutics","pharmaFlowCategory":"D","amount":"$19.0 million","upfrontCash":"Undisclosed","newsHeadline":"Merz Strengthens Partnership With Start-up Vensica and Invests up to $3 million","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Large molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Urology","graph2":"Phase III"}]

Find Clinical Drug Pipeline Developments & Deals by Vensica Therapeutics

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            This investment follows the strategic license and collaboration agreement signed in 2021 to utilize Merz’s botulinum neurotoxin A (XEOMIN®) for the innovative ultrasound-assisted delivery catheter of Vensica.

            Lead Product(s): IncobotulinumtoxinA

            Therapeutic Area: Urology Product Name: Xeomin

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Merz Therapeutics

            Deal Size: $19.0 million Upfront Cash: Undisclosed

            Deal Type: Partnership February 07, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY